These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 17679821)

  • 21. Would Janus' view on HDL be useful?
    Kasko M; Kasko V; Oravec S
    Bratisl Lek Listy; 2018; 119(4):245-248. PubMed ID: 29663823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?
    Rizzo M; Barylski M; Rizvi AA; Montalto G; Mikhailidis DP; Banach M
    Curr Pharm Des; 2013; 19(21):3858-68. PubMed ID: 23286436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Atherogenic dyslipidemia and residual risk. State of the art in 2014].
    Millán Núñez-Cortés J; Pedro-Botet Montoya J; Pintó Sala X;
    Clin Investig Arterioscler; 2014; 26(6):287-92. PubMed ID: 25450326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Importance of dyslipidaemia in cardiovascular disease: a point of view].
    Ascaso JF; Carmena R
    Clin Investig Arterioscler; 2015; 27(6):301-8. PubMed ID: 26363575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention.
    Millán J; Pintó X; Muñoz A; Zúñiga M; Rubiés-Prat J; Pallardo LF; Masana L; Mangas A; Hernández-Mijares A; González-Santos P; Ascaso JF; Pedro-Botet J
    Vasc Health Risk Manag; 2009; 5():757-65. PubMed ID: 19774217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Diabetic dyslipoproteinemia: beyond LDL].
    Merkel M
    Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes.
    Gonna H; Ray KK
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 1():6-16. PubMed ID: 31002453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What is the best choice for combination therapy in the management of dyslipidemia of metabolic syndrome?
    Turhan H; Yetkin E
    Cardiology; 2006; 105(3):139-40; author reply 141. PubMed ID: 16449809
    [No Abstract]   [Full Text] [Related]  

  • 30. Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.
    Catapano AL
    Nat Rev Cardiol; 2018 Jan; 15(2):75-76. PubMed ID: 29336436
    [No Abstract]   [Full Text] [Related]  

  • 31. [Reasons for a combination].
    Núñez-Cortés JM
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():40-1. PubMed ID: 25043547
    [No Abstract]   [Full Text] [Related]  

  • 32. [Beat therapeutic inertia in dyslipidemic patient management: A challenge in daily clinical practice] [corrected].
    Morales C; Mauri M; Vila L
    Clin Investig Arterioscler; 2014; 26(4):193-9. PubMed ID: 24646954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The lipid triad, or how to reduce residual cardiovascular risk?
    Girard-Mauduit S
    Ann Endocrinol (Paris); 2010 Mar; 71(2):89-94. PubMed ID: 20303470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholesterol goal attainment in hypertensive patients: the impact of metabolic syndrome components.
    Rodrigues CJ; Ribeiro HF; Ribeiro AB; Zanella MT; Batista MC
    Metab Syndr Relat Disord; 2012 Jun; 10(3):195-201. PubMed ID: 22313142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dyslipidemia therapy update: the importance of full lipid profile assessment.
    Menown IB; Murtagh G; Maher V; Cooney MT; Graham IM; Tomkin G
    Adv Ther; 2009 Jul; 26(7):711-8. PubMed ID: 19649582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New european guidelines for dyslipidemia].
    Riesen WF; Virgini V; Vogt B; Rodondi N
    Rev Med Suisse; 2012 Mar; 8(331):525-6, 528-30. PubMed ID: 22471115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The program of lowering of residual vascular risk (The Residual Vascular Risk Reduction Initiative). Part II. Methods of correction].
    Zubareva MIu; Susekov AV
    Kardiologiia; 2010; 50(9):64-70. PubMed ID: 21118169
    [No Abstract]   [Full Text] [Related]  

  • 38. Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges.
    Virani SS
    Tex Heart Inst J; 2011; 38(2):160-2. PubMed ID: 21494527
    [No Abstract]   [Full Text] [Related]  

  • 39. [Guidelines for the management of atherosclerotic diseases in diabetes mellitus].
    Kotake H; Oikawa S
    Nihon Rinsho; 2006 Nov; 64(11):2074-80. PubMed ID: 17087299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The surprising AIM-HIGH results are not surprising when viewed through a particle lens.
    Otvos JD
    J Clin Lipidol; 2011; 5(5):368-70. PubMed ID: 21981836
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.